BCL2L11 and cancer: Although these observations need to be confirmed using primary samples, they fit well with previous data indicating that cancer cells with high levels of AKT/ERK exhibit suppressed BIM expression [121,122], and they identify API5 as an immune-related prognostic biomarker.